ReviewClinical, cosmetic and investigational dermatology2026
From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review recent advances in the pathogenic mechanisms and treatment of vitiligo and to evaluate the evidence supporting Western medicine, traditional Chinese medicine, and integrative treatment strategies. Methods: This narrative review was based on a structured literature search of PubMed, China National Knowledge Infrastructure, and Wanfang databases, primarily covering the period from January 2015 to March 2026. The search terms included "vitiligo", "pathogenesis", "treatment", "JAK inhibitors", and "traditional Chinese medicine". Articles published in English and Chinese were considered. Eligible publications included clinical trials, systematic reviews, meta-analyses, observational studies, and representative mechanistic studies relevant to the pathogenesis or treatment of vitiligo. Duplicate publications, articles not directly related to vitiligo, and studies with insufficient methodological reporting were excluded. Results: Current evidence indicates that immune dysregulation and oxidative stress are central and interacting mechanisms in the initiation, progression, and recurrence of vitiligo. These mechanistic advances have supported the development of targeted and combination therapies, although the strength of evidence varies considerably among different interventions. Artificial intelligence-assisted phototherapy may improve lesion identification and irradiation planning, but current clinical evidence remains limited. JAK inhibitors, particularly topical ruxolitinib, represent an important mechanism-based therapeutic advance in non-segmental vitiligo. Surgical transplantation may provide effective repigmentation options for selected patients with stable vitiligo, although outcomes vary according to disease stability, lesion site, and surgical technique. Traditional Chinese medicine and integrative therapies may provide adjunctive clinical benefit, but the available evidence is limited by study heterogeneity and variable methodological quality. Conclusion: Future research should prioritize difficult-to-treat acral and mucosal lesions, relapse prevention, maintenance therapy, predictive biomarkers, and the long-term efficacy and safety of targeted and combination treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.